Notch Therapeutics

Please note: The information displayed on this page might be outdated.
Notch Therapeutics: Notch is an immune cell therapy company creating universally compatible, allogeneic (off-the-shelf) T cell therapies for the treatment of cancer and immune disorders. Notch’s technology platform uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and has the potential to deliver safer, consistently manufactured and more cost-effective cell immunotherapies to patients. At the core of Notch’s technology is the synthetic Engineered Thymic Niche (ETN) platform, which precisely controls the expansion and differentiation of stem cells in a process suitable for large-scale manufacturing, delivering fully defined, consistent, feeder-free and serum-free T cells that can be genetically tailored for any T cell-based immunotherapeutic application.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
North America
Disease Space
Immuno-Oncology
Listing
Private
Therapeutic Modalities
Cell Therapy
Website:
Address:
2405 Wesbrook Mall
4th Floor
Vancouver, BC V6T 1Z3
Canada

Company Participants at Spring Private Company Showcase

David J. Main
Notch Therapeutics, CEO
Prior to joining Abdera Pharma, David was the CEO of Aquinox. Mr. Main has over 25 years experience in the pharmaceutical industry and brings a demonstrated ability to grow and finance pharmaceutical development companies. As a co-founder of Aquinox, Mr. Main has overseen the advancement of the Company’s lead product, AQX-1125, from a target validation program to now entering Phase 3 studies. During this time he has also been responsible for the transition of Aquinox from a private to a NASDAQ-listed public company with over US$200 million raised to date in equity capital. Mr. Main was formerly the President and CEO of INEX Pharmaceuticals Corp. and, prior to INEX, was Vice President at QLT Inc., one of Canada’s inaugural biotech companies. Mr. Main began his career as a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C. He holds a B.Sc. (Pharmacy) and an MBA from the University of British Columbia (UBC). Mr. Main formerly served as the Chair of LifeSciences BC (formerly BC Biotech), is currently the Chair of BIOTECanada and a Director of BIO.org as well he also serves on a number of private and not-for-profit Boards.
Timothy Key
Notch Therapeutics, Director, Business Operations
Timothy Key joined Notch Therapeutics as Director, Business Operations after working on the company concept as part of his role at MaRS Innovation (now Toronto Innovation Acceleration Partners). Tim holds a Ph.D. in Microbiology and Immunology from Dalhousie University, and he trained in drug discovery and development of small molecules and biologics at the Center for Drug Research and Development (CDRD) in Vancouver.